Table 2 Clinical and pathological characteristics of 497 GIST patients
From: Gastrointestinal stromal tumor: 15-years’ experience in a single center
Age (years) | |
Median | 60 |
Range | 23-90 |
Sex, n (%) | |
Male | 278 (55.9) |
Female | 219 (44.1) |
Primary site of tumor, n (%) | |
Stomach | 293 (59.0) |
Duodenum | 31 (6.2) |
Small bowel | 112 (22.5) |
Large bowel | 4 (0.8) |
Rectum | 21 (4.2) |
Esophagus | 3 (0.6) |
Other (omentum, mesenterium and retroperitoneum ) | 33 (6.6) |
Clinical manifestation, n (%) | |
Abdominal discomfort | 184 (37.0) |
GI bleeding | 142 (28.6) |
Diagnosed at physical examination | 81 (16.3) |
Abdominal mass | 14 (2.8) |
Other (fever, fatigue, appetite and explored at surgery for other diseases) | 76 (15.3) |
IM therapy | |
As adjuvant therapy for primary disease | 96 |
As therapy for advanced disease (recurrent, metastatic, unresectable, or incomplete resected) | 46 |
Immunohistochemistry, n (%) | |
CD117 | 434 (87.3) |
CD34 | 399 (80.3) |
SMA | 119 (23.9) |
S-100 | 107 (21.5) |
DOG1 | 139 (93.3)* |